ArticleAmerican journal of nuclear medicine and molecular imaging2014
Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature.
Article in American journal of nuclear medicine and molecular imaging, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Diagnostic Performance of PET/CT Using 18F-FACBC in Prostate Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Highlights of articles published in annals of nuclear medicine 2016.European journal of nuclear medicine and molecular imaging · 2017Pooled it
- PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial.JAMA network open · 2021Trial
- Detection Accuracy of [World journal of nuclear medicine · 2025Article
- Review
- Utility of Lymphadenectomy in Prostate Cancer: Where Do We Stand?Journal of clinical medicine · 2022Review
- Standardization of the [Pharmaceuticals (Basel, Switzerland) · 2021Article
- External beam radiotherapy for prostate cancer: What are the current research trends and hotspots?Cancer medicine · 2021Article
- Preclinical Evaluation of the Copper-64 Labeled GRPR-Antagonist RM26 in Comparison with the Cobalt-55 Labeled Counterpart for PET-Imaging of Prostate Cancer.Molecules (Basel, Switzerland) · 2020Article
- A review of prostate cancer imaging, positron emission tomography, and radiopharmaceutical-based therapy.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2020Review
- Review
- Stability Evaluation and Stabilization of a Gastrin-Releasing Peptide Receptor (GRPR) Targeting Imaging Pharmaceutical.Molecules (Basel, Switzerland) · 2019Article
- Article
- Review
- Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.American journal of nuclear medicine and molecular imaging · 2018Review
- Potential of asphericity as a novel diagnostic parameter in the evaluation of patients withEJNMMI research · 2017Article
- Molecular radiotheragnostics in prostate cancer.Clinical medicine (London, England) · 2017Article
- PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies.European journal of nuclear medicine and molecular imaging · 2017Review
- Positron emission tomography (PET) in primary prostate cancer staging and risk assessment.Translational andrology and urology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Positron emission tomography (PET) with a number of tracers targeted to particular biological features of cancer has been explored for the imaging evaluation of patients with biochemical recurrence of prostate cancer after curative primary treatment. However, these reports are often heterogeneous in study design, patient cohorts, standards of reference for the imaging findings, data analysis, and data reporting. The aim of our study was to address these limitations by extracting and re-analyzing the PET detection data only from studies that satisfied pre-defined sets of patient selection criteria and verification standards. Our investigation analyzed the effects of 5 tracers ((18)F-fluorodeoxyglucose (FDG), (11)C-acetate (ACET), (11)C- or (18)F-choline (CHOL), anti-1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid (FACBC), and radiolabeled ligand targeted to prostate-specific membrane antigen (PSMA)), 2 treatment types (radical prostatectomy and radiation therapy), and whether the detected disease was local or metastatic, including lesion type (bone, lymph node, soft tissue). FDG exhibited the lowest detection rate for any suspected disease. ACET tended to be advantageous over CHOL in detecting local recurrence and lymph node lesions, even though the difference was not statistically significant. FACBC had greater likelihood of detecting local recurrence, when compared to CHOL, though this difference was not statistically significant. PSMA tended to show a higher proportion of patients with suspected disease compared to the other four tracers. Patients treated with radiation therapy had greater odds of displaying local recurrence on PET than those treated with radical prostatectomy. We also provide suggestions for future investigations that facilitate communication and the impact of the findings.
Indexed as
Identifiers
25250207PMC4171844What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.